Introduction

Glanzmann Thrombasthenia (GT) is a rare, inherited platelet disorder that severely impairs the body's ability to form blood clots. First identified by Dr. Eduard Glanzmann in 1918, this condition results from abnormalities in the glycoprotein IIb/IIIa (GPIIb/IIIa) complex on platelets, a critical receptor responsible for platelet aggregation during blood clot formation. As a result, individuals with GT experience prolonged bleeding even from minor injuries, presenting a significant health challenge.

GT is an autosomal recessive disorder, meaning that an individual must inherit defective copies of the relevant genes from both parents to manifest the disease. While it is rare globally, GT occurs more frequently in regions where consanguineous marriages are common, such as parts of the Middle East and South Asia.

Understanding the genetic basis of GT is crucial for improving diagnostic accuracy and developing effective treatments. Mutations in the ITGA2B and ITGB3 genes are responsible for the condition, and genetic research continues to unveil the molecular mechanisms behind the disorder. With advancements in genetic testing, it is now possible to detect these mutations early, allowing for more personalized approaches to management and potentially opening doors to gene therapies in the future.¹

Overview of platelet function and pathophysiology in glanzmann thrombasthenia

In normal hemostasis, platelets play a crucial role in preventing excessive bleeding by adhering to damaged blood vessels and aggregating to form a stable clot. Upon vascular injury, platelets are activated and bind to fibrinogen, an essential protein that bridges platelets together, forming a platelet plug. This aggregation process is mediated by the glycoprotein IIb/IIIa (GPIIb/IIIa) complex on the surface of platelets, a receptor that binds fibrinogen and other adhesive molecules necessary for proper clot formation.

In Glanzmann Thrombasthenia (GT), the primary defect lies in the absence or dysfunction of the GPIIb/IIIa complex due to mutations in the ITGA2B or ITGB3 genes, which encode the GPIIb and GPIIIa proteins, respectively. The deficiency or malfunction of this receptor disrupts the platelets' ability to aggregate and form clots, leading to impaired hemostasis. Despite the normal number and appearance of platelets, their function is severely compromised.

As a result, individuals with GT exhibit a range of bleeding disorders. Phenotypic consequences include mucocutaneous bleeding such as frequent nosebleeds (epistaxis), easy bruising, and prolonged bleeding from minor injuries. Other symptoms may include excessive bleeding during menstruation (menorrhagia), bleeding gums (gingival bleeding), and in severe cases, life-threatening haemorrhages. The severity of symptoms can vary, but the underlying cause is always linked to the inability of platelets to perform their essential role in clot formation, owing to the dysfunction of the GPIIb/IIIa complex.²

Molecular genetics of glanzmann thrombasthenia

Glanzmann Thrombasthenia (GT) is caused by mutations in the genes responsible for producing the glycoprotein IIb/IIIa (GPIIb/IIIa) complex, a critical component of platelet aggregation. The two primary genes involved in this process are ITGA2B and ITGB3, which encode the GPIIb and GPIIIa proteins, respectively. These two proteins combine to form the GPIIb/IIIa complex, which serves as a receptor on the surface of platelets, binding to fibrinogen and other adhesive molecules to mediate platelet aggregation during blood clot formation.

The ITGA2B gene, located on chromosome 17, encodes the GPIIb subunit, while the ITGB3 gene, also on chromosome 17, encodes the GPIIIa subunit. Together, these subunits form a functional receptor that undergoes conformational changes upon platelet activation, enabling the binding of fibrinogen and platelet aggregation. Mutations in either of these genes can result in a dysfunctional or absent GPIIb/IIIa complex, which prevents normal platelet aggregation and leads to the bleeding phenotype observed in GT.

Mutations in ITGA2B and ITGB3 are diverse and include missense, nonsense, and frameshift mutations. Missense mutations result in a single amino acid substitution, potentially altering the structure of the GPIIb/IIIa complex and impairing its function. Nonsense mutations introduce premature stop codons, leading to truncated proteins that cannot form a functional receptor. Frameshift mutations, caused by insertions or deletions, disrupt the genetic code, often leading to a nonfunctional protein product. Each type of mutation contributes to varying degrees of dysfunction in the GPIIb/IIIa complex, resulting in the range of bleeding severities seen in GT patients.³

Classification of glanzmann thrombasthenia based on genetic variants

Glanzmann Thrombasthenia (GT) is classified into several subtypes based on the presence and functionality of the GPIIb/IIIa complex and the specific genetic mutations involved. Understanding these subtypes is crucial for accurate diagnosis and tailored treatment approaches.

Type I Glanzmann Thrombasthenia is characterised by the complete or near-complete absence of the GPIIb/IIIa complex on platelet surfaces. This absence leads to severe bleeding tendencies due to the platelets' inability to aggregate properly. Common mutations associated with Type I include frameshift and nonsense mutations in the ITGA2B or ITGB3 genes, which result in truncated or nonfunctional GPIIb or GPIIIa proteins. These mutations prevent the assembly of the GPIIb/IIIa complex, severely impairing platelet function.

Type II Glanzmann Thrombasthenia is marked by the presence of the GPIIb/IIIa complex, but with significantly reduced functionality. In this subtype, the GPIIb/IIIa complex is expressed at normal levels, but its ability to bind fibrinogen and mediate platelet aggregation is compromised. This dysfunction is often due to missense mutations that alter the structure or function of the GPIIb or GPIIIa proteins, impairing their interaction with fibrinogen. Type II GT can vary in severity depending on the extent of functional impairment.

Variant Glanzmann Thrombasthenia presents unique functional abnormalities despite the normal expression of the GPIIb/IIIa complex. This subtype includes cases where the complex is present but exhibits abnormal behaviour, such as altered binding affinities or defective signal transduction pathways. Genetic causes for these variants may involve subtle changes in the GPIIb or GPIIIa proteins or associated signalling molecules, which do not entirely disrupt complex formation but impair its function.

Identifying these subtypes is clinically significant as it influences prognosis and treatment strategies. Type I cases may require more aggressive management, including platelet transfusions or gene therapy, whereas Type II and Variant cases might benefit from therapies aimed at enhancing platelet function or correcting specific molecular defects. Accurate classification helps provide targeted treatments and better predict clinical outcomes.⁴

Mechanisms of genetic mutations in ITGA2B and ITGB3

ITGA2B and ITGB3 genes are crucial for the proper function of the GPIIb/IIIa complex on platelets, and mutations in these genes lead to Glanzmann Thrombasthenia (GT). Here, we explore the molecular mechanisms of mutations in these genes and their impact on platelet function.

Molecular mechanisms leading to mutation in ITGA2B gene

Frameshift Mutations: Frameshift mutations in the ITGA2B gene result from insertions or deletions of nucleotides that alter the reading frame of the gene’s codons. These mutations lead to the production of truncated GPIIb proteins that lack essential functional domains. For example, a deletion of a few nucleotides might shift the reading frame, introducing a premature stop codon and leading to a nonfunctional or absent GPIIb protein.

Missense Mutations: Missense mutations involve a single nucleotide change that results in the substitution of one amino acid for another in the GPIIb protein. Such mutations can affect protein folding, stability, and the ability to interact with GPIIIa. This disruption impairs the proper assembly of the GPIIb/IIIa complex, leading to reduced platelet aggregation.

• Nonsense Mutations: Nonsense mutations introduce premature stop codons into the ITGA2B gene sequence, resulting in truncated GPIIb proteins. These truncated proteins are usually nonfunctional and cannot properly combine with GPIIIa to form the GPIIb/IIIa complex, severely compromising platelet function

Molecular mechanisms leading to mutation in ITGB3 gene

Structural Changes in GPIIIa Protein: Mutations in the ITGB3 gene often lead to structural alterations in the GPIIIa protein, affecting its ability to form a stable GPIIb/IIIa complex. For instance, missense mutations can cause conformational changes that hinder the protein’s interaction with GPIIb or fibrinogen, disrupting platelet aggregation.

• Specific Examples of Mutations: Notable mutations in ITGB3 include those that alter key residues in the GPIIIa protein’s integrin domain, essential for fibrinogen binding. For example, a mutation leading to a defect in the ligand-binding site can prevent the GPIIb/IIIa complex from binding to fibrinogen, thereby impairing clot formation

Genomic location and conservation

Both ITGA2B and ITGB3 are located on chromosome 17 and are highly conserved across species, reflecting their critical role in hemostasis. The evolutionary conservation of these genes underscores their importance in platelet function and the maintenance of blood clotting mechanisms across different organisms.

Genetic testing and detection

Modern genetic testing techniques have greatly advanced our ability to identify mutations in ITGA2B and ITGB3. Techniques such as Polymerase Chain Reaction (PCR) allow for the amplification of specific gene regions, while sequencing methods, including Sanger sequencing and Next-Generation Sequencing (NGS), provide comprehensive mutation profiles. These methods enable precise detection of both common and rare mutations, facilitating accurate diagnosis and personalized treatment strategies for GT.

In summary, mutations in the ITGA2B and ITGB3 genes disrupt the GPIIb/IIIa complex in various ways, leading to the bleeding disorders characteristic of Glanzmann Thrombasthenia. Advances in genetic testing continue to enhance our understanding and management of this condition.⁵

Inheritance patterns and genetic counselling in glanzmann thrombasthenia

Glanzmann Thrombasthenia (GT) follows an autosomal recessive inheritance pattern. This means that an individual must inherit two copies of the defective gene one from each parent to manifest the disorder. Each parent carries one normal and one mutated copy of the gene but typically does not exhibit symptoms, as they are carriers of the condition.

Carrier Status and Family Implications: Carriers of GT have one normal and one mutated allele for the ITGA2B or ITGB3 genes. While carriers do not show symptoms of the disorder, they can pass the mutated gene to their offspring. If both parents are carriers, there is a 25% chance with each pregnancy that the child will inherit both mutated alleles and thus develop GT, a 50% chance that the child will be a carrier and a 25% chance that the child will inherit neither mutated allele.

Importance of Genetic Counseling: For families affected by GT, genetic counselling is crucial. It provides information about the likelihood of passing the disorder to future children and discusses reproductive options. Prenatal genetic testing can detect mutations in a fetus, allowing families to make informed decisions about their pregnancy. Genetic counsellors also offer support for managing the condition and planning for future family planning.

Variability in Phenotypic Expression: The severity of GT can vary among individuals with the same genetic mutations, due to factors such as genetic background and environmental influences. Carriers do not exhibit symptoms, but homozygous individuals (those with two mutated alleles) can experience a range of bleeding manifestations depending on the specific mutations and their effects on GPIIb/IIIa function.⁷

Recent advances in genetic research on glanzmann thrombasthenia

Recent advancements in genetic research have significantly enhanced our understanding of Glanzmann Thrombasthenia (GT) and opened new avenues for treatment and diagnosis. 

Recent Discoveries: Advances in genomic technologies have identified a broader range of mutations in the ITGA2B and ITGB3 genes responsible for GT. Researchers have pinpointed novel mutations and characterized their impact on GPIIb/IIIa function. This expanded genetic knowledge improves diagnostic accuracy and helps in understanding the disease’s molecular basis.

Gene Therapy and CRISPR: Gene therapy holds promise for treating GT by directly addressing the genetic mutations. Techniques like CRISPR/Cas9 have emerged as powerful tools for gene editing, potentially allowing for the correction of mutations in ITGA2B and ITGB3. Early research and clinical trials are exploring these approaches, aiming to restore the normal function of GPIIb/IIIa in affected individuals. However, challenges such as delivering the gene-editing tools effectively to target cells and ensuring long-term safety and efficacy remain significant.

Advances in Prenatal Genetic Testing: The field of prenatal genetic testing has seen remarkable progress, with advanced diagnostic tools like next-generation sequencing (NGS) providing comprehensive mutation profiles. These technologies enable early detection of GT in fetuses, allowing for informed decision-making and early intervention if necessary.

Personalized Medicine: With the growing understanding of the specific genetic mutations involved in GT, personalized medicine is becoming a reality. Tailoring treatments based on individual genetic profiles is now possible, potentially leading to more effective and targeted therapeutic strategies. This approach ensures that patients receive the most appropriate care based on the exact nature of their genetic mutations and disease severity.

These advancements are paving the way for more precise diagnostics, innovative treatments, and improved management of Glanzmann Thrombasthenia.⁷

FAQs

What is glanzmann thrombasthenia?  

Answer: Glanzmann Thrombasthenia (GT) is a rare inherited blood disorder characterized by defective platelet function due to abnormalities in the glycoprotein IIb/IIIa (GPIIb/IIIa) complex. This impairment affects the platelets' ability to aggregate and form blood clots, leading to excessive bleeding and bruising.

How is glanzmann thrombasthenia inherited?  

Answer: GT is inherited in an autosomal recessive pattern. This means an individual must inherit two defective copies of the ITGA2B or ITGB3 genes one from each parent to develop the condition. Parents who each carry one mutated gene are carriers and typically do not show symptoms of the disorder.

What are the common symptoms of glanzmann thrombasthenia?  

Answer: Common symptoms of GT include frequent nosebleeds (epistaxis), bleeding gums (gingival bleeding), easy bruising, prolonged bleeding from minor cuts or injuries, and heavy menstrual bleeding (menorrhagia). In severe cases, individuals may experience life-threatening haemorrhages.

How is glanzmann thrombasthenia diagnosed?  

Answer: Diagnosis of GT involves a combination of blood tests and genetic analysis. Blood tests can reveal impaired platelet aggregation, while genetic testing identifies mutations in the ITGA2B or ITGB3 genes. Techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are used for accurate mutation detection.

What treatment options are available for glanzmann thrombasthenia?  

Answer: Treatment for GT primarily focuses on managing bleeding symptoms and preventing complications. Options include platelet transfusions to provide functional platelets, antifibrinolytic agents to reduce bleeding, and in some cases, medications to enhance platelet function. Research into gene therapy and other advanced treatments is ongoing.

Can genetic counselling help families affected by glanzmann thrombasthenia?  

Answer: Yes, genetic counselling is highly beneficial for families affected by GT. It provides information about the risk of passing the disorder to future children, discusses reproductive options, and offers support in understanding the implications of genetic testing. Prenatal genetic testing can also help in early diagnosis and informed decision-making during pregnancy.

Conclusion

Glanzmann Thrombasthenia (GT) is a rare genetic disorder characterized by defective platelet function due to abnormalities in the glycoprotein IIb/IIIa (GPIIb/IIIa) complex. This complex is essential for platelet aggregation and clot formation, and its dysfunction leads to severe bleeding problems. The disorder is inherited in an autosomal recessive pattern, meaning that both parents must carry and pass on mutated copies of the ITGA2B or ITGB3 genes for the child to develop GT.

The ITGA2B gene encodes the GPIIb subunit, while the ITGB3 gene encodes the GPIIIa subunit. Mutations in these genes can lead to various forms of GT:

• Type I GT is characterized by the absence or very low levels of the GPIIb/IIIa complex
• Type II GT involves the presence of the complex but with reduced function
• Variant GT features unique functional abnormalities despite normal GPIIb/IIIa expression

Recent advances in genetic research have revealed new mutations and provided insights into the molecular mechanisms underlying the disorder. Emerging therapies, such as gene therapy and CRISPR, offer the potential to correct genetic mutations and restore normal platelet function. Additionally, improvements in prenatal genetic testing and personalized medicine are enhancing the accuracy of diagnosis and the efficacy of treatment strategies.

Genetic counselling plays a crucial role in managing GT, offering families information on inheritance risks, reproductive options, and support in understanding and planning for the condition. Overall, these advancements contribute to better diagnosis, treatment, and management of Glanzmann Thrombasthenia.